Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterResearch Letter

Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience

Rosario Foti, Elisa Visalli, Giorgio Amato, Ylenia Dal Bosco, Roberta Foti and Giacomo Baccano
The Journal of Rheumatology March 2023, 50 (3) 458-459; DOI: https://doi.org/10.3899/jrheum.220333
Rosario Foti
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rosario Foti
Elisa Visalli
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elisa Visalli
Giorgio Amato
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ylenia Dal Bosco
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ylenia Dal Bosco
Roberta Foti
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roberta Foti
Giacomo Baccano
1Division of Rheumatology, A.O.U. “Policlinico San Marco”, 95123 Catania, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giacomo Baccano
  • For correspondence: gbaccano@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Apremilast, an oral selective phosphodiesterase 4 inhibitor, has been shown to be a safe and effective treatment for psoriasis and psoriatic arthritis (PsA).1-3

Data from pivotal trials4,5 and a recent retrospective evaluation in an Italian multicentric cohort of patients with PsA treated with apremilast6 showed a retention rate of 72% after 6 months and approximately 50% after 1 year of follow-up.

We retrospectively examined drug survival in 62 patients treated with apremilast for PsA at San Marco Hospital Rheumatology Unit in Catania from March 2018 to January 2022. PsA was diagnosed according to the Classification Criteria for Psoriatic Arthritis (CASPAR).7 This analysis was approved by the ethics committee of Azienda Ospedaliero Universitaria Policlinico “G. Rodolico-San Marco,” Catania, Italy (approval no. 16019). Patient consent was not required due to the retrospective design of this study.

Apremilast was given as first-line therapy in 30 patients, as second line in 8 patients, as third line in 9 patients, as fourth line in 2 patients, and as sixth line in 2 patients. To date, we have treated 62 patients with PsA. Data on demographics, comorbidities (including BMI), and disease characteristics (duration since onset of PsA and type of involvement) were collected at the first visit. Clinical characteristics at timpoints 0, 6, and 12 months are shown (Table). The majority of patients showed a peripheral pattern; of note, only 5 patients out of 62 had axial involvement.

View this table:
  • View inline
  • View popup
Table.

Clinical characteristics at 6 and 12 months.

Follow-up data differed among patients, due to the different timepoints at which patients started therapy. We have follow-up data for 49, 44, 16, and 5 patients at 6, 12, 24, and 36 months, respectively.

We calculated the retention rate of apremilast using a Kaplan-Meier curve. We found that 88% of patients were still on treatment after 6 months and 73% after 1 year (Figure). In our cohort, apremilast showed high retention rates even when it was used as a second-line treatment or beyond, and even in patients with long disease duration.

Figure.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

Twelve-month retention rate of apremilast.

A possible explanation for this high retention rate may be patient selection. In our study, most of the patients treated with apremilast were multifailure, with major comorbidities and/or contraindications to other biologics. For this reason, patients aware of frequent side effects, especially occurring at the beginning of the treatment, are more inclined to continue the therapy. Moreover, appropriate management of side effects could be a further explanation of the high drug survival.

Footnotes

  • RF has received grants and/or honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB. The remaining authors declare no conflicts of interest relevant to this article.

  • Copyright © 2023 by the Journal of Rheumatology

REFERENCES

  1. 1.↵
    1. Papp K,
    2. Reich K,
    3. Leonardi CL, et al
    . Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM1]). J Am Acad Dermatol 2015;73:37-49.
    OpenUrlCrossRefPubMed
  2. 2.
    1. Paul C,
    2. Cather J,
    3. Gooderham M, et al
    . Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol 2015;173:1387-99.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Schett G,
    2. Wollenhaupt J,
    3. Papp K, et al
    . Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64:3156-67.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Kavanaugh A,
    2. Mease PJ,
    3. Gomez-Reino JJ, et al
    . Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020-6.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Edwards CJ,
    2. Blanco FJ,
    3. Crowley J, et al
    . Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 2016;75:1065-73.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Favalli EG,
    2. Conti F,
    3. Selmi C, et al
    . Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. Clin Exp Rheumatol 2020;381:19-26.
    OpenUrl
  7. 7.↵
    1. Taylor W,
    2. Gladman D,
    3. Helliwell P,
    4. Marchesoni A,
    5. Mease P,
    6. Mielants H; CASPAR Study Group
    . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 50, Issue 3
1 Mar 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience
Rosario Foti, Elisa Visalli, Giorgio Amato, Ylenia Dal Bosco, Roberta Foti, Giacomo Baccano
The Journal of Rheumatology Mar 2023, 50 (3) 458-459; DOI: 10.3899/jrheum.220333

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience
Rosario Foti, Elisa Visalli, Giorgio Amato, Ylenia Dal Bosco, Roberta Foti, Giacomo Baccano
The Journal of Rheumatology Mar 2023, 50 (3) 458-459; DOI: 10.3899/jrheum.220333
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Response to Treatment With Tofacitinib in 11 Patients With Refractory Granulomatosis With Polyangiitis
  • Isolated Neutropenia in Systemic Lupus Erythematosus
Show more Research Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire